10x Genomics, Inc. Class A Common Stock insider trading
TXGfinancial statementsForm 4 filings on EDGAR91 transactions since Nov 9, 2024
From August 12, 2026 to November 9, 2026, 0 insiders at 10x Genomics, Inc. Class A Common Stock bought $0 of stock in the open market, and 6 sold $11M. Officers and directors accounted for $0 of purchases and $11M of sales. The last reported transaction was an open-market sale by Suliman Shehnaaz on September 22, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through September 24, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $11MAug 12, 2026 – Nov 9, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Nov 6, 2026. Insider data through Nov 9, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
91 transactions from November 9, 2024 to November 9, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | Suliman Shehnaaz | Director | open-market sale10b5-1 | 292 | $78.20 | $23K | 29,223 | Sep 24, 2026 |
| Sep 22, 2026 | Suliman Shehnaaz | Director | open-market sale10b5-1 | 614 | $79.51 | $49K | 28,609 | Sep 24, 2026 |
| Sep 22, 2026 | Suliman Shehnaaz | Director | open-market sale10b5-1 | 1,325 | $80.82 | $107K | 27,284 | Sep 24, 2026 |
| Sep 22, 2026 | Suliman Shehnaaz | Director | open-market sale10b5-1 | 2,270 | $81.67 | $185K | 25,014 | Sep 24, 2026 |
| Sep 22, 2026 | Suliman Shehnaaz | Director | open-market sale10b5-1 | 1,222 | $82.28 | $101K | 23,792 | Sep 24, 2026 |
| Sep 22, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 1,000 | $78.23 | $78K | 1M | Sep 24, 2026 |
| Sep 22, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 2,000 | $79.62 | $159K | 1M | Sep 24, 2026 |
| Sep 22, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 9,300 | $80.90 | $752K | 1M | Sep 24, 2026 |
| Sep 22, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 9,900 | $81.83 | $810K | 1M | Sep 24, 2026 |
| Sep 22, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 2,800 | $82.36 | $231K | 1M | Sep 24, 2026 |
| Sep 9, 2026 | Taich Adam | Chief Financial Officer | open-market sale10b5-1 | 1,206 | $63.68 | $77K | 361,526 | Sep 11, 2026 |
| Sep 9, 2026 | Taich Adam | Chief Financial Officer | open-market sale10b5-1 | 31,428 | $64.31 | $2M | 330,098 | Sep 11, 2026 |
| Sep 9, 2026 | Taich Adam | Chief Financial Officer | open-market sale10b5-1 | 13,754 | $65.26 | $898K | 316,344 | Sep 11, 2026 |
| Sep 3, 2026 | Stuelpnagel John R | Director | open-market sale | 7,012 | $60.66 | $425K | 341,424 | Sep 8, 2026 |
| Sep 3, 2026 | Stuelpnagel John R | Director | open-market sale | 6,814 | $62.11 | $423K | 334,610 | Sep 8, 2026 |
| Sep 3, 2026 | Stuelpnagel John R | Director | open-market sale | 6,174 | $62.61 | $387K | 328,436 | Sep 8, 2026 |
| Sep 1, 2026 | Saxonov Serge | Chief Executive Officer, Director | gift | 100 | $0.00 | — | 1M | Sep 3, 2026 |
| Aug 26, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 3,500 | $63.02 | $221K | 1M | Aug 28, 2026 |
| Aug 26, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 6,494 | $63.98 | $415K | 1M | Aug 28, 2026 |
| Aug 26, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 492 | $64.75 | $32K | 1M | Aug 28, 2026 |
| Aug 24, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale | 18,545 | $63.02 | $1M | 1M | Aug 26, 2026 |
| Aug 24, 2026 | Taich Adam | Chief Financial Officer | open-market sale | 17,166 | $63.02 | $1M | 362,732 | Aug 26, 2026 |
| Aug 24, 2026 | Hindson Benjamin J. | See Remarks, Director | open-market sale | 13,818 | $63.02 | $871K | 488,182 | Aug 26, 2026 |
| Aug 24, 2026 | Suliman Shehnaaz | Director | open-market sale10b5-1 | 561 | $62.73 | $35K | 31,161 | Aug 26, 2026 |
| Aug 24, 2026 | Suliman Shehnaaz | Director | open-market sale10b5-1 | 1,646 | $63.97 | $105K | 29,515 | Aug 26, 2026 |
| Aug 20, 2026 | Saxonov Serge | Chief Executive Officer, Director | gift | 4,000 | $0.00 | — | 1M | Aug 24, 2026 |
| Aug 14, 2026 | Teichmann Sarah A. | Director | open-market sale10b5-1 | 2,273 | $57.15 | $130K | 28,058 | Aug 17, 2026 |
| Aug 13, 2026 | Teichmann Sarah A. | Director | open-market sale10b5-1 | 5,278 | $57.29 | $302K | 30,331 | Aug 17, 2026 |
| Aug 11, 2026 | Stuelpnagel John R | Director | open-market sale | 17,000 | $57.58 | $979K | 351,436 | Aug 13, 2026 |
| Aug 11, 2026 | Stuelpnagel John R | Director | open-market sale | 3,000 | $58.73 | $176K | 348,436 | Aug 13, 2026 |
| Jun 22, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 8,527 | $33.29 | $284K | 1M | Jun 24, 2026 |
| Jun 22, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 9,991 | $34.28 | $343K | 1M | Jun 24, 2026 |
| Jun 22, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 9,821 | $35.32 | $347K | 1M | Jun 24, 2026 |
| Jun 22, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 1,661 | $36.16 | $60K | 1M | Jun 24, 2026 |
| Jun 16, 2026 | Suliman Shehnaaz | Director | open-market sale10b5-1 | 5,359 | $32.59 | $175K | 32,086 | Jun 18, 2026 |
| Jun 16, 2026 | Suliman Shehnaaz | Director | open-market sale10b5-1 | 364 | $33.27 | $12K | 31,722 | Jun 18, 2026 |
| Jun 4, 2026 | Teichmann Sarah A. | Director | award | 8,829 | $0.00 | — | 35,609 | Jun 8, 2026 |
| Jun 4, 2026 | Suliman Shehnaaz | Director | award | 8,829 | $0.00 | — | 37,445 | Jun 8, 2026 |
| Jun 4, 2026 | Stuelpnagel John R | Director | award | 8,829 | $0.00 | — | 368,436 | Jun 8, 2026 |
| Jun 4, 2026 | Popovits Kimberly J | Director | award | 8,829 | $0.00 | — | 37,445 | Jun 8, 2026 |
| Jun 4, 2026 | Mateo Alan | Director | award | 8,829 | $0.00 | — | 85,877 | Jun 8, 2026 |
| Jun 4, 2026 | Kosaraju Sridhar | Director | award | 8,829 | $0.00 | — | 65,278 | Jun 8, 2026 |
| May 26, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 10,718 | $24.71 | $265K | 1M | May 27, 2026 |
| May 22, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 18,175 | $24.44 | $444K | 1M | May 27, 2026 |
| May 22, 2026 | Hindson Benjamin J. | See Remarks, Director | open-market sale | 11,595 | $24.44 | $283K | 502,000 | May 27, 2026 |
| May 22, 2026 | Taich Adam | Chief Financial Officer | open-market sale | 15,098 | $24.44 | $369K | 379,898 | May 27, 2026 |
| Apr 14, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 5,000 | $24.56 | $123K | 1M | Apr 16, 2026 |
| Mar 24, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 5,000 | $19.52 | $98K | 1M | Mar 25, 2026 |
| Mar 23, 2026 | Saxonov Serge | Chief Executive Officer, Director | open-market sale10b5-1 | 10,000 | $19.13 | $191K | 1M | Mar 25, 2026 |
| Mar 3, 2026 | Saxonov Serge | Chief Executive Officer, Director | gift | 2,750 | $0.00 | — | 1M | Mar 4, 2026 |
Who the insiders are
Everyone who reported a transaction since November 9, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer, Director | Sep 22, 2026 | open-market sale | 1M | — | $7M (22) | 19 of 22 |
| Taich Adam | Chief Financial Officer | Sep 9, 2026 | open-market sale | 361,526 | — | $5M (7) | 3 of 7 |
| Stuelpnagel John R | Director | Sep 3, 2026 | open-market sale | 341,424 | — | $2M (5) | 0 of 5 |
| Hindson Benjamin J. | See Remarks, Director | Aug 24, 2026 | open-market sale | 488,182 | — | $1M (4) | 0 of 4 |
| Suliman Shehnaaz | Director | Sep 22, 2026 | open-market sale | 29,223 | — | $792K (9) | 9 of 9 |
| Teichmann Sarah A. | Director | Aug 14, 2026 | open-market sale | 28,058 | — | $579K (3) | 3 of 3 |
| Mateo Alan | Director | Jun 4, 2026 | award | 85,877 | — | — | — |
| Popovits Kimberly J | Director | Jun 4, 2026 | award | 37,445 | — | — | — |
| Kosaraju Sridhar | Director | Jun 4, 2026 | award | 65,278 | — | — | — |
Questions
Are 10x Genomics, Inc. Class A Common Stock insiders buying or selling?
Over the twelve months to November 9, 2026, 6 insiders at 10x Genomics, Inc. Class A Common Stock sold $17M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $17M. Only open-market purchases and sales are counted.
Who sold the most 10x Genomics, Inc. Class A Common Stock stock in the last year?
Saxonov Serge (Chief Executive Officer, Director) sold $7M in 22 open-market sales over the twelve months to November 9, 2026.
Do 10x Genomics, Inc. Class A Common Stock executives sell under 10b5-1 plans?
34 of the 50 open-market sales in the last twelve months (68%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on 10x Genomics, Inc. Class A Common Stock
- 10x Genomics, Inc. Class A Common Stock financial statements
- 1 tracked fund holding TXG
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.